NO. 91414

INFUSION SERVICES AND EQUIPMENT

Effective: 03/01/2026
Committee Review: 02/11/2026
Last reviewed: 08/31/2026

Instructions for use: This document is for informational purposes only. Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion. Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

Policy scope: This policy addresses Infusion services including external and implantable infusion pumps.

Related policies:

- Continuous Glucose Monitoring and Insulin Pumps No. 91466

I. MEDICAL NECESSITY CRITERIA

A. External Infusion Pumps

1. Preauthorization may be required for certain indications as determined by the medical department.

2. An external infusion pump may be considered medically necessary for infusion of an FDA approved drug for treatment of *any* of the following conditions:
   a. Severe chronic pain or post procedural pain
   b. Chemotherapy for cancer
   c. Intractable cancer pain

d. Fungal or viral infection
e. Heart failure
f. Pulmonary Hypertension
g. Symptomatic hypercalcemia due to cancer
h. Primary immune deficiency disorder
i. Chronic inflammatory demyelinating polyneuropathy
j. Idiopathic Parkinson Disease
k. Chronic iron overload

3. Insulin Pumps:
   a. Commercial / Medicare: Both newly prescribed and replacement insulin pumps must be prior authorized and are medically necessary when applicable InterQual® criteria are met. (see medical policy Continuous Glucose Monitoring and Insulin Pumps Policy No. 91466).

B. Implantable Infusion Pumps

1. Pre-authorization for implantable infusion pumps may be required for specific indications as determined by the medical department. They must be FDA approved to administer the drug prescribed. *Note: For Code C2626 - infusion pump, nonprogrammable, temporary (implantable), prior authorization is not required.*

2. Chronic Pain Management: An implantable infusion pump to administer opioid drugs epidurally or intrathecally must be prior authorized and is medically necessary for severe chronic malignant or non-malignant pain when applicable InterQual® criteria are met.

3. Intrahepatic Chemotherapy: Implantable infusion pumps for continuous hepatic artery infusion of chemotherapy are medically necessary for primary or metastatic liver cancer if metastasis is limited to the liver and **one** of the following apply:
   a. Tumor is unresectable, or
   b. Patient refused surgical excision of the tumor.

4. Anti–Spasmodic Drugs: An implantable infusion pump to administer anti-spasmodic drugs (e.g. baclofen) intrathecally for severe chronic spasticity is a covered benefit if **both** of the following apply:
   a. Failure of less invasive methods (e.g. oral anti-spasmodic) either due to inadequate spasm control or side effects.
   b. Favorable response to a trial intrathecal dose of anti-spasmodic drug.

5. Thromboembolic Disease: The use of an implantable infusion pump to administer heparin for recurrent thromboembolic disease has not been proven to be safe or effective and is not medically necessary.

II. CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) COVERAGE DETERMINATION

Any applicable federal or state mandates will take precedence over this medical coverage policy.

Medicare: Refer to the CMS Online Manual System (IOMs) and Transmittals.
For the most current applicable CMS National Coverage Determination (NCD)/Local Coverage Determination (LCD)/Local Coverage Article (LCA) refer to CMS Medicare Coverage Database.

The information below is current as of the review date for this policy. However, the coverage issues and policies maintained by CMS are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. MAC jurisdiction for purposes of local coverage determinations is governed by the geographic service area where the Medicare Advantage plan is contracted to provide the service. Please refer to the Medicare Coverage Database website for the most current applicable NCD, LCD, LCA, and CMS Online Manual System/Transmittals.

National Coverage Determinations (NCDs)	
NCD - Infusion Pumps (280.14)	
Local Coverage Determinations (LCDs)	
CGS Administrators, LLC	LCD - External Infusion Pumps (L33794)
First Coast Service Options, Inc.	None identified
Wellpoint Federal (formerly National Government Services, Inc.)	None identified
Noridian Healthcare Solutions	LCD - External Infusion Pumps (L33794)
Novitas Solutions, Inc.	None identified
Palmetto GBA	LCD - Implantable Infusion Pump (L33461)
WPS Insurance Corporation	None identified

III. BACKGROUND

External infusion pumps are commonly used for drug delivery to administer antibiotics, analgesia, chemotherapy, blood products, parenteral nutrition, etc. The drug delivery catheter may be inserted into a peripheral or central vein, a subcutaneous space, implanted in an artery or other compartment (e.g. epidural). Some infusion pumps are

designed for stationary use while others, called ambulatory infusion pumps, are designed to be portable or wearable.

Implantable infusion pumps are used for long-term site-specific drug therapy to various nervous and vascular compartments (e.g. epidural, hepatic artery, subarachnoid). Implantable infusion pumps are surgically implanted and able to provide a constant or a variable rate of infusion. These types of pumps allow long-term access and site-specific drug delivery, thereby allowing more mobility. An adverse event or suspected adverse reaction is considered "serious" if, in the view of Priority Health, it results in any of the following outcomes: Death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the member and may require medical or surgical intervention to prevent one of the outcomes listed.

IV. GUIDELINES / POSITION STATEMENTS

Medical/Professional Society	Guideline
National Comprehensive Cancer Network (NCCN)	pain.pdf ped_all.pdf all.pdf
International Society for Heart and Lung Transplantation (ISHLT)	International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024
National Institute for Health and Care Excellence (NICE).	Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms
Infusion Nurses Society	Infusion Therapy Standards of Practice, 9th Edition - PubMed
American Society of Clinical Oncology	JPR_A_315585 2139..2164

V. REGULATORY (US FOOD AND DRUG ADMINISTRATION)

See U.S. Food & Drug Administration (FDA) Medical Device Databases for the most current information.

Device	Premarket Approval, 513(f)(2)(De Novo), or 510(k) Number	Notice date
Moog CURLIN 8000 Ambulatory Infusion System (Moog Medical)	K242660	10/3/2024
CADD®- Solis Ambulatory Infusion Pump	K170982	08/24/2017
Nipro Surefuser Ambulatory infusion pump	K051828	12/15/2005
AutoFuser Ambulatory Infusion Pump (ALGOS, LC)	K041585	08/26/2004
ambIT® PIB PCA V1.5 Pump	K162165	11/18/2016
ON-Q* Pump with Bolus (Avanos Medical)	K181360	3/22/2019
The ambITTM Pump (Sorenson Medical, Inc.)	K033325	11/06/2003
FreedomEdge® Syringe Infusion System (KORU Medical Systems)	K214045	04/29/2022
Sapphire Infusion Pump (Q Core Medical LTD)	K123049	10/16/2013
VLV Associates Disposable Ambulatory Infusion Pump (VLV Associates, INC.)	K940406	09/02/1994
Prometra® Programmable Pump System (Flowonix Medical)	P080012/S068	01/12/2022
Synchromed (Medtronic) SynchroMed™ II SynchroMed™ III	P860004	09/10/1996 09/12/2003 10/06/2023 02/12/2026
Arrow International 3000 Series Pump Codman/Arrow	P890055	01/11/1999
Implantable Remodulin® Infusion System (Medtronic)	P140032	12/22/2017

VI. CODING

See Also:
Priority Health Infusion Services Supplies Billing Policy No. 041

ICD-10 Codes that may support medical necessity

G89.0	Central Pain Syndrome
G89.21-G89.29	Chronic pain due to trauma
G89.3	Neoplasm related pain (acute) (chronic)
G89.4	Chronic pain syndrome
R52	Pain, unspecified
G90.50-G90.9	Complex regional pain syndrome I
G95.11	Acute infarction of spinal cord (embolic) (non-embolic)
G95.19	Other vascular myelopathies
M08.1	Juvenile ankylosing spondylitis
M45.0-M45.9	Ankylosing spondylitis
M48.00-M48.9	Spinal Stenosis
M51.0-M51.9	Thoracic, thoracolumbar, and lumbosacral intervertebral disc disorders with myelopathy
M54.00-M54.9	Panniculitis affecting regions of neck and back
I27.0	Primary pulmonary hypertension
I27.20	Pulmonary hypertension, unspecified
I27.21	Secondary pulmonary arterial hypertension
I27.22	Pulmonary hypertension due to left heart disease
I27.23	Pulmonary hypertension due to lung diseases and hypoxia
I27.24	Chronic thromboembolic pulmonary hypertension
I27.29	Other secondary pulmonary hypertension
I27.83	Eisenmenger's syndrome
C22.0-C22.9	Liver cell carcinoma
Z51.11	Encounter for antineoplastic chemotherapy
Z51.12	Encounter for antineoplastic immunotherapy
R25.0 – R25.9	Abnormal involuntary movements
G04.1	Tropical spastic paraplegia
G35	Multiple sclerosis
G80.0-G80.9	Cerebral palsy
G81.10-G81.14	Spastic hemiplegia

CPT/HCPCS Codes
External pumps (except insulin pumps) are rental only.

- **Intra-Arterial Infusion Pumps**

Implantable Intra-Arterial Pump Procedures

36260	Insertion of implantable intra-arterial infusion pump (e.g., for chemotherapy of liver)
36261	Revision of implanted intra-arterial infusion pump
36262	Removal of implanted intra-arterial infusion pump

Maintenance

96522	Refilling and maintenance of implantable pump or reservoir for drug delivery, systemic (e.g., intravenous, intra-arterial)

- **Intrathecal/Epidural Drug Infusion Pumps**

Implantation, Replacement and Removal

62360	Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir
62361	Implantation or replacement of device for intrathecal or epidural drug infusion; non-programmable pump
62362	Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or without programming
62365	Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion

Pump Analysis, Programming, and Refills

62367	Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming or refill
62368	Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming
62369	Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill
62370	Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional)

Associated Equipment

E0785 Implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement
E0786 Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter)

- **Intraventricular Infusion Systems**

Implantation

61215 Insertion of subcutaneous reservoir, pump or continuous infusion system for connection to Ventricular catheter

- **Implantable Pump Refills and Maintenance**

95990 Refilling and maintenance of implantable pump or reservoir for drug delivery, spinal (intrathecal, epidural) or brain (intraventricular), includes electronic analysis of pump, when performed;
95991 Refilling and maintenance of implantable pump or reservoir for drug delivery, spinal (intrathecal, epidural) or brain (intraventricular), includes electronic analysis of pump, when performed; requiring skill of a physician or other qualified health care professional

- **Implantable Infusion Pump Devices**

Programmable

C1772 Infusion pump, programmable (implantable)
E0783 Infusion pump system, implantable, programmable (includes all components, e.g., pump, catheter, connectors, etc.)

Non-Programmable

C1891 Infusion pump, non-programmable, permanent (implantable)
C2626 Infusion pump, nonprogrammable, temporary (implantable)
E0782 Infusion pump, implantable, nonprogrammable (includes all components, e.g., pump, catheter, connectors, etc.)

- **External and Ambulatory Infusion Pumps**

External Pumps

E0779 Ambulatory infusion pump mechanical reusable for infusion 8 hours or greater
E0780 Ambulatory infusion pump mechanical reusable for infusion less than 8 hours
E0781 Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient
K0455 Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol)

External Infusion Pump Supplies

A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drug separately) (Not covered for Priority Medicaid)
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) (Not covered for Priority Medicaid)
A4223	Infusion supplies not used with external infusion pump, per cassette or bag (list drugs separately) (Not covered for Priority Medicaid)

- **Disposable Post-Surgical Non-Opioid Infusion Pumps**

C9804	Elastomeric infusion pump (e.g., On-Q* pump with bolus), including catheter and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023) (Not Separately payable for Fully Funded and Self-Funded)
C9806	Rotary peristaltic infusion pump (e.g., ambIT pump), including catheter and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023) (Not Separately payable for Fully Funded and Self-Funded)

VII. MEDICAL NECESSITY REVIEW

Prior authorization for certain drugs, devices, services and procedures may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service or procedure is medically necessary. For more information, refer to the Priority Health Provider Manual.

To access InterQual guidelines: Log into Priority Health Prism → Authorizations → Authorization Criteria Lookup.

Individual case review may allow coverage for care or treatment that is investigational yet promising for the conditions described. Requests for individual consideration require prior plan approval. All determinations of coverage for experimental, investigational, or unproven treatment will be made by a Priority Health medical director or clinical pharmacist. The exclusion of coverage for experimental, investigational, or unproven treatment may be reviewed for exception if the condition is either a terminal illness, or a chronic, life threatening, severely disabling disease that is causing serious clinical deterioration.

VIII. APPLICATION TO PRODUCTS

Coverage is subject to the member's specific benefits. Group-specific policy will supersede this policy when applicable.

- **HMO/EPO**: This policy applies to insured HMO/EPO plans.
- **POS**: This policy applies to insured POS plans.

- **PPO**: This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.
- **ASO**: For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.
- **INDIVIDUAL**: For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.
- **MEDICARE**: Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, this policy applies.
- **MEDICAID/HEALTHY MICHIGAN PLAN**: For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule. If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual, the Michigan Medicaid Provider Manual will govern. If there is a discrepancy or lack of guidance in the Michigan Medicaid Provider Manual, the Priority Health contract with Michigan Medicaid will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.

IX. REFERENCES

Society and Professional Guidelines

1. Centers for Medicare and Medicaid Services. LCD - External Infusion Pumps (L33794) (Accessed January 27, 2025).
2. Centers for Medicare and Medicaid Services, NCD - Infusion Pumps (280.14) (Accessed January 27, 2025)
3. International Society for Heart and Lung Transplantation (ISHLT). Guidelines for the Care of Heart Transplant Candidates. Published 2024. Accessed January 5, 2026. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024.
4. Michigan Department of Health and Human Services. Medicaid Provider Manual. State of Michigan. (Accessed January 27, 2025).
5. National Comprehensive Cancer Network (NCCN). Acute Lymphoblastic Leukemia. Version 2.2025. NCCN Clinical Practice Guidelines in Oncology. Published 2025. Accessed January 5, 2026. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
6. National Comprehensive Cancer Network (NCCN). Adult Cancer Pain. Version 2.2025. NCCN Clinical Practice Guidelines in Oncology. Published 2025. Accessed January 5, 2026. https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf
7. National Comprehensive Cancer Network (NCCN). Pediatric Acute Lymphoblastic Leukemia. Version 2.2025. NCCN Clinical Practice Guidelines in Oncology. Published 2025. Accessed January 5, 2026. https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf
8. Nickel B, Gorski L, Kleidon T, et al. Infusion Therapy Standards of Practice, 9th Edition. *J Infus Nurs*. 2024;47(1S Suppl 1):S1-S285. doi:10.1097/NAN.0000000000000532
9. US Food & Drug Administration. CFR Code of Federal Regulations Title 21. (Accessed January 27, 2025).

Chronic Pain

1. Abd-Elsayed A, Karri J, Michael A, Bryce D, Sun J, Lee M, Orhurhu V, Deer T. Intrathecal Drug Delivery for Chronic Pain Syndromes: A Review of Considerations in Practice Management. Pain Physician. 2020 Nov;23(6):E591- E617. PMID: 33185379.
2. Cho JH, Lee JH, Song KS, Hong JY, Joo YS, Lee DH, Hwang CJ, Lee CS. Treatment Outcomes for Patients with Failed Back Surgery. Pain Physician. 2017 Jan-Feb;20(1):E29-E43. PMID: 28072795.
3. Hamza M, Doleys DM, Saleh IA, Medvedovsky A, Verdolin MH, Hamza M. A Prospective, Randomized, Single-Blinded, Head-to-Head Long-Term Outcome Study, Comparing Intrathecal (IT) Boluses With Continuous Infusion Trialing Techniques Prior to Implantation of Drug Delivery Systems (DDS) for the Treatment of Severe Intractable Chronic Nonmalignant Pain. Neuromodulation. 2015 Oct;18(7):636-48; discussion 649. doi: 10.1111/ner.12342. Epub 2015 Aug 26. PMID: 26307558.
4. Judith A. Paice et al. Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. J Clin Oncol 41, 914-930(2023). DOI:10.1200/JCO.22.02198
5. Lloyd ECO, Dempsey B, Romero L. Complex Regional Pain Syndrome. Am Fam Physician. 2021 Jul 1;104(1):49-55. PMID: 34264598.
6. Herring EZ, Frizon LA, Hogue O, M et al. Long-term Outcomes Using Intrathecal Drug Delivery Systems in Complex Regional Pain Syndrome. Pain Med. 2019 Mar 1;20(3):515-520. doi: 10.1093/pm/pny104. PMID: 29889241.
7. Schultz DM, Orhurhu V, Khan F, Hagedorn JM, Abd-Elsayed A. Patient Satisfaction Following Intrathecal Targeted Drug Delivery for Benign Chronic Pain: Results of a Single-Center Survey Study. Neuromodulation. 2020 Oct;23(7):1009-1017. doi: 10.1111/ner.13167. Epub 2020 May 6. PMID: 32378289; PMCID: PMC7687151.
8. Schultz DM, Abd-Elsayed A, Calodney A, Stromberg K, Weaver T, Spencer RJ. Targeted Drug Delivery for Chronic Nonmalignant Pain: Longitudinal Data From the Product Surveillance Registry. Neuromodulation. 2021 Oct;24(7):1167-1175. doi: 10.1111/ner.13353. Epub 2021 Jan 15. PMID: 33449428; PMCID: PMC8597001.
9. Shearer HM, Verville L, Côté P, Hogg-Johnson S, Fehlings DL. Clinical course of pain intensity in individuals with cerebral palsy: A prognostic systematic review. Dev Med Child Neurol. 2023;65(1):24-37. doi:10.1111/dmcn.15358

Intrahepatic Chemotherapy

1. Holster JJ, El Hassnaoui M, Franssen S, et al. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2022 Sep;29(9):5528- 5538. doi: 10.1245/s10434-022-11439-x. Epub 2022 Mar 16. PMID: 35294656; PMCID: PMC9356931.
2. Kuemmerli C, Hess V, Dutkowski P, et al. Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-

Level Evidence. Pharmacology. 2024;109(2):86-97. doi: 10.1159/000537887. Epub 2024 Feb 16. PMID: 38368862; PMCID: PMC11008720.
3. Thiels CA, D'Angelica MI. Hepatic artery infusion pumps. J Surg Oncol. 2020 Jul;122(1):70-77. doi: 10.1002/jso.25913. Epub 2020 Mar 25. PMID: 32215927; PMCID: PMC9014308.

Anti-Spasmodic Drugs

1. Hasnat MJ, Rice JE. Intrathecal baclofen for treating spasticity in children with cerebral palsy. Cochrane Database Syst Rev. 2015 Nov MEDICAL POLICY No. 91414-R22 Infusion Services & Equipment Page 8 of 9 13;2015(11):CD004552. doi: 10.1002/14651858.CD004552.pub2. PMID: 26563961; PMCID: PMC9361875.
2. Masrour M, Zare A, Presedo A, Nabian MH. Intrathecal baclofen efficacy for managing motor function and spasticity severity in patients with cerebral palsy: a systematic review and meta-analysis. *BMC Neurol*. 2024;24(1):143. Published 2024 Apr 27. doi:10.1186/s12883-024-03647-7
3. Otero-Luis I, Saz-Lara A, Cavero-Redondo I, Pascual-Morena C, Martínez-García I, Nuñez de Arenas-Arroyo S. Effectiveness of the intrathecal baclofen pump in the treatment of spasticity of different aetiologies: A systematic review and meta-analysis. *Neurologia (Engl Ed)*. 2025;40(6):577-585. doi:10.1016/j.nrleng.2025.06.011
4. Penn RD, Gianino JM, York MM. Intrathecal baclofen for motor disorders. Mov Disord. 1995 Sep;10(5):675-7. doi: 10.1002/mds.870100524. PMID: 8552124.

SUMMARY OF CHANGES

Additions:

- Added links for related medical policies.

Deletions:

- Removed coding section language stating: "Prior authorization not required unless charges exceed $1,000 for Commercial or Medicare members, or $500 for Medicaid members."

Past committee review dates: 10/1995, 12/1999, 12/2001, 11/2002, 11/2003,11/2004, 10/2005, 10/2006, 10/2007, 10/2008,10/2009, 04/2010, 04/2011, 04/2012, 04/2013, 05/2014, 05/2015, 02/2016, 02/2017, 05/2017, 11/2017, 08/2018, 08/2019, 11/2019, 08/2020, 05/2021, 11/2021, 05/2022, 05/2023, 05/2024, 02/2025, 02/2026

AMA CPT Copyright Statement: All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.